公开(公告)号：WO2005108368A1

公开(公告)日：2005-11-17

申请号：PCT/US2005/015304

申请日：2005-04-29

Applicant: ABBOTT LABORATORIES ,  LINK, James, T. ,  PLIUSHCHEV, Marina, A. ,  ROHDE, Jeffrey, J. ,  WODKA, Dariusz ,  PATEL, Jyoti, R. ,  SHUAI, Qi

Inventor： LINK, James, T. ,  PLIUSHCHEV, Marina, A. ,  ROHDE, Jeffrey, J. ,  WODKA, Dariusz ,  PATEL, Jyoti, R. ,  SHUAI, Qi

IPC: C07D213/06

CPC classification number: C07D213/06 ,  C07C237/04 ,  C07C237/24 ,  C07C2601/02 ,  C07C2603/74 ,  C07D207/02 ,  C07D209/08 ,  C07D213/24 ,  C07D213/72 ,  C07D213/74 ,  C07D213/85 ,  C07D223/16 ,  C07D253/06 ,  C07D257/04 ,  C07D277/64 ,  C07D295/15 ,  C07D295/185 ,  C07D471/08 ,  C07D491/04

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征以及其它疾病和病症的用途 由过度的糖皮质激素作用介导。

公开(公告)号：WO2009026422A3

公开(公告)日：2009-02-26

申请号：PCT/US2008/073830

申请日：2008-08-21

Applicant: ABBOTT LABORATORIES ,  BITNER, R., Scott ,  BROWMAN, Kaitlin, E ,  BRUNE, Michael, E ,  CHEN, Yixian ,  DINGES, Jurgen ,  DRESCHER, Karla ,  JACOBSON, Peer ,  JAE, Hwan-soo ,  KURUKULASURIYA, Ravi ,  LINK, James, T. ,  MADAR, David, J. ,  PATEL, Jyoti, R. ,  PLIUSHCHEV, Marina, A. ,  ROHDE, Jeffrey, J. ,  RUETER, Lynne, E. ,  SHUAI, Qi ,  SORENSEN, Bryan, K. ,  WANG, Jiahong ,  WICKE, Karsten, M. ,  WINN, Martin ,  WODKA, Dariusz ,  YEH, Vince ,  YONG, Hong

Inventor： BITNER, R., Scott ,  BROWMAN, Kaitlin, E ,  BRUNE, Michael, E ,  CHEN, Yixian ,  DINGES, Jurgen ,  DRESCHER, Karla ,  JACOBSON, Peer ,  JAE, Hwan-soo ,  KURUKULASURIYA, Ravi ,  LINK, James, T. ,  MADAR, David, J. ,  PATEL, Jyoti, R. ,  PLIUSHCHEV, Marina, A. ,  ROHDE, Jeffrey, J. ,  RUETER, Lynne, E. ,  SHUAI, Qi ,  SORENSEN, Bryan, K. ,  WANG, Jiahong ,  WICKE, Karsten, M. ,  WINN, Martin ,  WODKA, Dariusz ,  YEH, Vince ,  YONG, Hong

IPC: A61K31/495 ,  A61K31/445 ,  C07C233/23 ,  C07D471/02

Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.

公开(公告)号：WO2003105850A1

公开(公告)日：2003-12-24

申请号：PCT/US2003/018959

申请日：2003-06-17

Applicant: ABBOTT LABORATORIES

Inventor： COLLINS, Christine, A. ,  GAO, Ju ,  KYM, Philip, R. ,  LEWIS, Jared, C. ,  SOUERS, Andrew, J. ,  VASUDEVAN, Anil ,  WODKA, Dariusz

IPC: A61K31/47

CPC classification number: C07D215/38 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D411/12 ,  C07D413/12

Abstract: The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, which antagonize the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor and are useful for the prevention or treatment of eating disorders, weight gain and obesity.

Abstract translation: 本发明涉及通过黑色素浓缩激素受体拮抗黑色素浓缩激素（MCH）的作用的式（I）化合物或其治疗上合适的盐或前药，并且可用于预防或治疗饮食 疾病，体重增加和肥胖。

公开(公告)号：EP1250332A1

公开(公告)日：2002-10-23

申请号：EP00986489.3

申请日：2000-12-15

Applicant: Abbott Laboratories

Inventor： BASHA, Fatima, Z. ,  HINMAN, Mira, M. ,  KOPECKA, Hana, A. ,  SEARLE, Xenia, B. ,  SOWIN, Thomas, J. ,  WODKA, Dariusz ,  SUROWY, Carol ,  FALTYNEK, Connie, R.

IPC: C07D309/04 ,  C07D295/20 ,  C07D309/12 ,  C07D405/12 ,  C07D417/12 ,  C07C275/32 ,  C07D207/12 ,  C07D295/08 ,  C07D241/08 ,  C07D405/04 ,  C07D235/26 ,  A61K31/35 ,  A61K31/40 ,  A61K31/41 ,  A61K31/445

CPC classification number: C07D295/096 ,  C07C275/32 ,  C07D207/12 ,  C07D235/26 ,  C07D241/08 ,  C07D295/205 ,  C07D295/215 ,  C07D309/04 ,  C07D309/12 ,  C07D405/04 ,  C07D405/12 ,  C07D417/12

Abstract: A method of inhibiting interleukin 5 gene expression in a mammal comprising administering to a mammal in need of such treatment a pharmaceutically effective amount of one or more compounds selected from formula (I) and/or from formula (II).

公开(公告)号：EP1751108A1

公开(公告)日：2007-02-14

申请号：EP05742013.5

申请日：2005-04-29

Applicant: ABBOTT LABORATORIES

Inventor： LINK, James T. ,  PLIUSHCHEV, Marina A. ,  ROHDE, Jeffrey J. ,  WODKA, Dariusz ,  PATEL, Jyoti R. ,  SHUAI, Qi

IPC: C07D213/06 ,  C07D213/24 ,  C07D213/72 ,  C07D207/02 ,  A61K31/44 ,  A61K31/445

CPC classification number: C07D213/06 ,  C07C237/04 ,  C07C237/24 ,  C07C2601/02 ,  C07C2603/74 ,  C07D207/02 ,  C07D209/08 ,  C07D213/24 ,  C07D213/72 ,  C07D213/74 ,  C07D213/85 ,  C07D223/16 ,  C07D253/06 ,  C07D257/04 ,  C07D277/64 ,  C07D295/15 ,  C07D295/185 ,  C07D471/08 ,  C07D491/04

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖，脂质障碍，代谢综合征以及其它疾病和病症的用途 由过度的糖皮质激素作用介导。

公开(公告)号：EP1534703A2

公开(公告)日：2005-06-01

申请号：EP03760268.7

申请日：2003-06-11

Applicant: ABBOTT LABORATORIES

Inventor： BLACKBURN, Christopher ,  LAI, Su-jen ,  LEE, Jennifer, G. ,  MAGUIRE, Martin ,  PATANE, Michael, A. ,  LAMARCHE, Matthew, J. ,  CULLIS, Courtney, A. ,  BROWN, James ,  VASUDEVAN, Anil ,  FREEMAN, Jennifer, C. ,  MULHERN, Mathew, M. ,  LYNCH, John, K. ,  GAO, Ju ,  WODKA, Dariusz ,  SOUERS, Andrew, J. ,  IYENGAR, Rajesh

IPC: C07D405/00

CPC classification number: C07D405/14 ,  C07D401/14 ,  C07D405/12 ,  C07D409/14 ,  C07D413/14

Abstract: This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1). The compounds are represented by formula (I): where m is zero or one, n is zero to two, Y is oxygen or -N (R )-, R , R , R , R , R , R , and Ring A are defined in the specification. Coumarin and quinolone compounds where R and R together form a fused benzo ring are preferred. The invention also provides compounds of formula (VI) where the coumarin moiety is replaced by a quinazolinone ring. The compounds are useful for treating MCH-R1-related disorders, particularly overweight conditions including obesity.